Be wary of side effects and risks when using arimoclomol

Arimoclomol (arimoclomol), as a heat shock protein activator, currently joins forces with miglustat to provide a new way to treat neurological symptoms for patients with C Niemann-Pick disease (NPC). NPCIt is a rare genetic disease. Abnormal metabolism of fat substances in the patient's body causes the accumulation of harmful substances in the organs, which in turn causes neurological and brain problems. Although the exact mechanism of action of arelomol needs to be further explored, it has shown certain efficacy in clinical trials, bringing new hope to NPC patients.

However, the use of arelomol is not without risks, and its potential side effects and related risks require great attention. Clinical trial data indicate that arelomol may cause hypersensitivity reactions such as urticaria and angioedema. Specifically, about 6% of patients reported urticaria and angioedema (swelling of the eyes, lips, genitals, hands, and feet), and 3% reported only urticaria. These reactions mostly occur within the first two months of treatment. Once a patient experiences a severe allergic reaction, the medication should be discontinued immediately; for mild or moderate reactions, the medication should also be suspended and treated accordingly, and the patient's symptoms should be closely monitored until they subside.

In addition, arelomol may cause an increase in serum creatinine levels, but this increase is not associated with changes in glomerular function. Clinical trials have shown that patients' serum creatinine levels increased on average from baseline by 10% to 20%, mainly in the first month of treatment. Therefore, alternative methods that do not rely on creatinine are recommended for assessment of renal function during treatment. Thankfully, the increase in creatinine levels is reversible after discontinuation of the drug.

Of note, arelomol has embryofetal toxicity. Animal studies have shown that use of this drug during pregnancy may cause damage to the embryo. Therefore, female patients should fully understand the possible risks to the fetus and take effective contraceptive measures before using arelomol. It is important to inform the health care provider if the patient is pregnant or planning to become pregnant so that the need for treatment and potential risks can be evaluated.

In nursing mothers, it is unknown whether arelomol passes into breast milk. Therefore, patients should consult with their healthcare provider to determine the best way to feed their infant while taking this medication.

Additionally, animal studies have shown that arelomol may have negative effects on fertility. In an animal study, oral administration of arelomol resulted in a significant decrease in male and female fertility and increased preimplantation loss. It is unclear whether these effects are reversible. Therefore, patients who are planning to have children should fully understand the potential risks and discuss relevant precautions with their doctor before using this drug.

In summary, arelomol provides a new treatment option for NPC patients, but its side effects and risks cannot be ignored. Patients should closely monitor their physical condition during use and maintain close communication with the medical team to jointly ensure the safety and effectiveness of treatment.

Reference link: https://www.drugs.com/miplyffa.html